
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte's stock outlook is bolstered by a significant year-over-year revenue growth, primarily driven by a 10% increase in Jakafi demand across its cancer indications, along with a strong commercial launch of Niktivmo. The company's adjustment of fiscal year 2025 guidance to a projected revenue range of $4.23B to $4.32B highlights their confidence in sustaining growth, particularly with Jakafi's updated revenue expectations of $3.05B to $3.075B. Additionally, the performance of Opzelura, which exceeded expectations with $188M in sales, underscores the expanding market potential in dermatology, reinforcing Incyte's diverse portfolio and growth trajectory.
Bears say
Incyte faces a challenging outlook primarily due to the erosion of pricing power for its leading drug, Jakafi, alongside poor performance anticipated from its earlier-stage pipeline. Significant risks include disruptions to its base business caused by poor uptake, reimbursement challenges, strong competition, and potential safety concerns regarding marketed products. The company may encounter further setbacks with its ongoing clinical trials, which could hinder the extension of Jakafi's life cycle and lead to greater-than-expected declines in sales growth.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares